Abstract

Background: There is emphasis on timely administration of thrombolysis and clot retrieval but not antithrombotic therapy within 48 h for ischemic stroke (frequency of 64% in Australia and 97% in North America). We planned to assess the time metrics and variables associated with delaying antithrombotics (antiplatelet and anticoagulant therapy) administration.Methods: This was a retrospective study at Monash Health over 12 months in 2015. We plotted the cumulative event and mapped the key drivers (dimensionless variable Shapley value/SV) of antithrombotics.Results: There were 42 patients with transient ischemic attack/TIA and 483 with ischemic stroke [mean age was 71.8 ± 15.4; 56.0% male; nil by mouth (NBM) 74.5 and 49.3% of patients received “stat” (immediate and one off) dose antithrombotics]. The median time to imaging for the patients who did not have stroke code activated was 2.3 h (IQR 1.4–3.7), from imaging to dysphagia screen was 14.6 h (IQR 6.2–20.3), and from stopping NBM to antithrombotics was 1.7 h (IQR 0–16.5). TIA patients received antithrombotics earlier than those with ischemic stroke (90.5 vs. 86.5%, p = 0.01). Significant variables in regression analysis for time to antithrombotics were time to dysphagia screen (β 0.20 ± 0.03, SV = 3.2), nasogastric tube (β 19.8 ± 5.9, SV = −0.20), Alteplase (β 8.6 ± 3.6, SV = −1.9), stat dose antithrombotic (β −18.9 ± 2.9, SV = −10.8) and stroke code (β −5.9 ± 2.5, SV = 2.8). The partial correlation network showed that the time to antithrombotics increased with delay in dysphagia screen (coefficient = 0.33) and decreased if “stat” dose of antithrombotics was given (coefficient = −0.32).Conclusion: The proportion of patients receiving antithrombotics within 48 h was higher than previously reported in Australia but remained lower than the standard achieved in North American hospitals. Our process map and network analysis show avenues to shorten the time to antithrombotic.

Highlights

  • There has beensignificant emphasis on hyperacute therapies for acute ischemic stroke in the advent of endovascular clot retrieval and thrombolytic therapies [1]

  • The current analysis is restricted to the 525 patients with transient ischemic attack (TIA) (n = 42) and ischemic stroke (n = 483) in whom both time to antithrombotic therapy and dysphagia screen were available (age 71.8 ± 15.4, male = 56.0%, NIHSS on admission 4 (IQR 2–10)

  • Among patients having antithrombotics charted for immediate administration, there was a significant difference (p < 0.01) in the proportion of patients receiving aspirin (197 of 221 or 89.1%) vs. other antithrombotics (26 of 38 or 60.5%)

Read more

Summary

Introduction

There has beensignificant emphasis on hyperacute therapies for acute ischemic stroke in the advent of endovascular clot retrieval and thrombolytic therapies [1]. Investigators from Get with the Guidelines have set a minimal threshold of 85% as optimal for antithrombotic administration within 48 h. They have demonstrated an improvement in antithrombotic administration within 48 h from 91.5 to 97.0% over 5 years [6], using their performance improvement program. The aim of this study is to assess the time and the relationship among the variables associated with delay to antithrombotic therapy. There is emphasis on timely administration of thrombolysis and clot retrieval but not antithrombotic therapy within 48 h for ischemic stroke (frequency of 64% in Australia and 97% in North America). We planned to assess the time metrics and variables associated with delaying antithrombotics (antiplatelet and anticoagulant therapy) administration

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call